Dr Stuart Onions

Dr Stuart Onions has over 15 years drug discovery experience. He has held a variety of positions at Sygnature Discovery being promoted to his current position in 2020.  Having benefitted from a broad range of approaches and tactics to deliver optimal preclinical candidates, he has a profound flair of servicing, influencing and guiding biotechnology companies through the discovery process.

Stuart has previously led multiple medicinal chemistry programs delivering five compounds to ongoing clinical trials. More recently, two first-in-class preclinical anti-infectives therapeutic agents have been discovered under his supervision. He is recognised as an inventor on over thirty patents and has authored eleven papers.

Stuart holds a first class M.Chem degree and Ph.D. in supra-molecular chemistry. He also serves as a non-executive Director of Peak Proteins, a CRO specialising in the production, supply and crystallisation of proteins.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…